Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare disease treatments; HHS greenlights the compounding of six unapproved
Directly affected
- LLY Eli Lilly+22.4% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.
- JNJ Johnson & Johnson-1.7% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- PFE Pfizer+5.5% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- MRK Merck+1.9% 18d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- ABBV AbbVie+7.8% 30d
AbbVie (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| LLY | -8.42% | +0.54% | base | after close | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | after close | after close | after close | after close |
| XBI | +1.67% | +0.67% | base | after close | after close | after close | after close |
| JNJ | +1.93% | +2.66% | base | after close | after close | after close | after close |
| PFE | -1.67% | +1.73% | base | after close | after close | after close | after close |
| MRK | -2.47% | +3.37% | base | after close | after close | after close | after close |
| ABBV | +0.13% | +3.12% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review BioSpace
Source: BioSpace
The price since 4 Nov 2026: Select Sector Spdr Tr (XLV) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | three days earlier | +3.12% | final price |
| ABBV | five days earlier | +0.13% | final price |
| Johnson & Johnson (JNJ) | three days earlier | +2.66% | final price |
| Johnson & Johnson (JNJ) | five days earlier | +1.93% | final price |
| Eli Lilly (LLY) | three days earlier | +0.54% | final price |
| Eli Lilly (LLY) | five days earlier | -8.42% | final price |
| Merck (MRK) | three days earlier | +3.37% | final price |
| Merck (MRK) | five days earlier | -2.47% | final price |
| Pfizer (PFE) | three days earlier | +1.73% | final price |
| Pfizer (PFE) | five days earlier | -1.67% | final price |
| Spdr Series Trust (XBI) | three days earlier | +0.67% | final price |
| Spdr Series Trust (XBI) | five days earlier | +1.67% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +0.48% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.31% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 35 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 57 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 75 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 77 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 51 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies tied to this story
- XLV Select Sector Spdr Tr
For “Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
- XBI Spdr Series Trust
For “Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
- LLY Eli Lilly
In “Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- JNJ Johnson & Johnson
In “Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 4 Nov 2026 story “Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- MRK Merck
For “Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
On 4 Nov 2026, “Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review” is the story that connects Select Sector Spdr Tr (XLV) to this story.
The link for Select Sector Spdr Tr (XLV) is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
Price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1131.55 and 1447.86 across 20 sessions. The latest close on file is 1409.39.
What the saved facts support for Select Sector Spdr Tr (XLV)
46 out of 100
“Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.